

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

SUIT-2

RRID:CVCL_3172

Type: Cell Line

Proper Citation

RRID:CVCL_3172

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3172

Proper Citation: RRID:CVCL_3172

Description: Cell line SUIT-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic ductal adenocarcinoma

Defining Citation: [PMID:1391733](#), [PMID:3102439](#), [PMID:11169959](#), [PMID:11787853](#), [PMID:11854916](#), [PMID:12800145](#), [PMID:19077451](#), [PMID:20215515](#), [PMID:21607521](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SUIT-2

Synonyms: Suit-2, SUIT 2, SUIT2, Suit2, SUIzo Tumor-2

Cross References: BTO:BTO_0003493, CLO:CLO_0037114, EFO:EFO_0006495, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:365, BioSample:SAMN03472902, BioSample:SAMN10988018, cancercellines:CVCL_3172, Cell_Model_Passport:SIDM00371, Cosmic:710872, Cosmic:755300, Cosmic:808161, Cosmic:918051, Cosmic:1108340, Cosmic:1320464, Cosmic:1534322, Cosmic:1995647, Cosmic:2664046, Cosmic-CLP:1240219,

DepMap:ACH-000652, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10797-110I5, GDSC:1240219, GEO:GSM244426, GEO:GSM244427, GEO:GSM827218, GEO:GSM887657, GEO:GSM888749, GEO:GSM1588615, GEO:GSM1588627, GEO:GSM1670489, IARC_TP53:16745, JCRB:JCRB1094, LiGeA:CCLE_481, LINCS_LDP:LCL-1729, Lonza:1079, PharmacDB:SUIT2_1507_2019, PRIDE:PXD030304, Progenetix:CVCL_3172, TKG:TKG 0705, Wikidata:Q54970817

ID: CVCL_3172

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260830T000036+0000

Ratings and Alerts

No rating or validation information has been found for SUIT-2.

No alerts have been found for SUIT-2.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Ma B, et al. (2026) MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer. Molecular cancer research : MCR.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Cell reports, 45(5), 117314.

Gong D, et al. (2025) Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. Science advances, 11(42), eadx0632.

Nishikubo K, et al. (2025) Sustained reductions in valine and isoleucine mediate anti-cancer pharmacological effects of inhibiting amino acid transporter LAT1 in cancer cells. Cancer & metabolism, 13(1), 46.

Khine HEE, et al. (2025) Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways. Scientific reports, 15(1), 11376.

Dobersch S, et al. (2025) HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. Nature communications, 16(1), 4866.

Campos AD, et al. (2025) A STAT3/integrin axis accelerates pancreatic cancer initiation and progression. *Cell reports*, 44(8), 116010.

Cunniff PJ, et al. (2025) KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. *Nature communications*, 16(1), 9996.

Ishihara S, et al. (2025) Stiff extracellular matrix activates the transcription factor ATF5 to promote the proliferation of cancer cells. *iScience*, 28(3), 112057.

Alruwaili MM, et al. (2024) A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers. *Cell reports. Medicine*, 5(3), 101434.

Zhang S, et al. (2024) Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. *Cell death discovery*, 10(1), 124.

Shrestha H, et al. (2024) The Janus kinase 1 is critical for pancreatic cancer initiation and progression. *Cell reports*, 43(5), 114202.

Dcona MM, et al. (2023) Combined Targeting of NAD Biosynthesis and the NAD-dependent Transcription Factor C-terminal Binding Protein as a Promising Novel Therapy for Pancreatic Cancer. *Cancer research communications*, 3(10), 2003.

Zhang J, et al. (2023) Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer. *Cancers*, 15(19).

Vall??s-Mart?? A, et al. (2023) Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma. *Cell reports*, 42(6), 112581.

Yoon SJ, et al. (2023) Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. *Cancer research*, 83(9), 1426.

Kuroda Y, et al. (2023) Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F-labeled rBC2LCN lectin. *Cancer science*, 114(8), 3364.

Zeng S, et al. (2022) CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. *Journal of experimental & clinical cancer research : CR*, 41(1), 241.

Abt ER, et al. (2022) Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. *Cell reports*, 38(2), 110236.

He H, et al. (2022) Identification of Genes Associated with Liver Metastasis in Pancreatic Cancer Reveals PCSK6 as a Crucial Mediator. *Cancers*, 15(1).